Abstract:Abstract Background The benefit of targeted therapy for renal cell carcinoma (RCC) is largely crippled by drug resistance. Rapid disease progression and poor prognosis occur in patients with drug resistance. New treatments demand prompt exploration for clinical therapies. Ubiquitin-specific peptidase 39 (USP39) serves as the pro-tumor factor in several previous studies of other malignant tumors. To investigate the function and mechanism of USP39 in promoting malignant proliferation and angiogenesis of RCC. Methods We applied ONCOMINE database to analyze the correlation between USP39 expression level and the clinical characteristics of RCC. USP39 knockdown or overexpression plasmids were transfected into 786-O and ACHN cells. The HUVEC received cell supernatants of 786-O and ACHN cells with knockdown or overexpression USP39.The effect of USP39 on RCC was evaluated by MTT assay, cell cycle analysis, colony formation assay and tubule formation assay. The interaction between USP39 and VEGF-A alternative splicing was assessed by affinity purification and mass spectrometry, co-immunoprecipitation and Western blot assays. Results The mRNA expression level of USP39 in RCC was significantly higher than that in normal renal tissue (P < 0.001), and negatively correlated with the survival rate of RCC patients (P < 0.01). Silencing of USP39 in 786-O and ACHN cells inhibited cell proliferation and colony formation, and induced S phase arrest. USP39 overexpression significantly increased the number of tubules (P < 0.05) and branches (P < 0.01) formed by HUVEC cells, and USP39 knockdown produced an opposite effect (P < 0.05). The USP39 (101–565) fragment directly mediated its binding to SRSF1 and SRPK1, and promoted the phosphorylation of SRSF1 to regulate VEGF-A alternative splicing. USP39 knockdown upregulated the expression of VEGF-A 165b , and USP39 overexpression downregulated the expression of VEGF-A 165b significantly (both P < 0.05). Conclusion USP39 acted as a pro-tumor factor by motivating the malignant biological processes of RCC, probably through inhibiting VEGF-A 165b alternative splicing and regulating SRSF1 and SRPK1. USP39 may prove to be a potential therapeutic target for RCC. Graphic abstract

Reduced USP39 expression inhibits malignant proliferation of medullary thyroid carcinoma in vitro

Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma*

USP39 promotes the growth of human hepatocellular carcinoma in vitro and in vivo

Knockdown of USP39 Induces Cell Cycle Arrest and Apoptosis in Melanoma

USP39 regulates the growth of SMMC-7721 cells via FoxM1.

Targeting Ubiquitin-Specific Protease 22 Suppresses Growth and Metastasis of Anaplastic Thyroid Carcinoma.

USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A165b alternative splicing via regulating SRSF1 and SRPK1

USP39-mediated Deubiquitination of Cyclin B1 Promotes Tumor Cell Proliferation and Glioma Progression

Knockdown of Ubiquitin-Specific Peptidase 39 Inhibited the Growth of Osteosarcoma Cells and Induced Apoptosis in Vitro.

Ubiquitin-specific Peptidase 39 Regulates the Process of Proliferation and Migration of Human Ovarian Cancer Via P53/p21 Pathway and EMT

Lentivirus-Mediated Silencing of Mphosph8 Inhibits Mtc Proliferation and Enhances Apoptosis

USP39 stabilizes β-catenin by deubiquitination and suppressing E3 ligase TRIM26 pre-mRNA maturation to promote HCC progression

Knocking down USP39 Inhibits the Growth and Metastasis of Non-Small-Cell Lung Cancer Cells through Activating the p53 Pathway

USP39-mediated deubiquitination of Cyclin B1 at Lys242 promotes tumor cell cycle G2/M transition and glioma progression

USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma

USP39 Mediates P21-Dependent Proliferation and Neoplasia of Colon Cancer Cells by Regulating the P53/p21/cdc2/cyclin B1 Axis.

USP44 Inactivation Accelerates the Progression of Thyroid Cancer by Inducing Ubiquitylation and Degradation of P21.

Upregulated Mir-9-3p Promotes Cell Growth and Inhibits Apoptosis in Medullary Thyroid Carcinoma by Targeting BLCAP.

Silencing of TCTN1 Inhibits Proliferation, Induces Cell Cycle Arrest and Apoptosis in Human Thyroid Cancer

Prognostic Significance of USP22 As an Oncogene in Papillary Thyroid Carcinoma

Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.